[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TW570797B - Pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus - Google Patents

Pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus Download PDF

Info

Publication number
TW570797B
TW570797B TW087117536A TW87117536A TW570797B TW 570797 B TW570797 B TW 570797B TW 087117536 A TW087117536 A TW 087117536A TW 87117536 A TW87117536 A TW 87117536A TW 570797 B TW570797 B TW 570797B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
patent application
scope
pharmaceutical composition
Prior art date
Application number
TW087117536A
Other languages
English (en)
Chinese (zh)
Inventor
Jaikrishna Patel
Hamish Ross
Robin Price
Jeffrey Roger Granett
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of TW570797B publication Critical patent/TW570797B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW087117536A 1997-06-05 1998-10-23 Pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus TW570797B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
TW570797B true TW570797B (en) 2004-01-11

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
TW087117536A TW570797B (en) 1997-06-05 1998-10-23 Pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus

Country Status (29)

Country Link
EP (1) EP0998284A1 (es)
JP (1) JP2001521553A (es)
KR (1) KR20010013410A (es)
CN (3) CN1112926C (es)
AP (1) AP1214A (es)
AR (2) AR008198A1 (es)
AU (1) AU8215098A (es)
BG (1) BG104048A (es)
BR (1) BR9810405A (es)
CA (2) CA2292629C (es)
CO (1) CO4940400A1 (es)
DZ (1) DZ2510A1 (es)
EA (1) EA002384B1 (es)
GB (1) GB9711683D0 (es)
HU (1) HUP0004070A3 (es)
ID (1) ID24264A (es)
IL (1) IL133074A0 (es)
MX (1) MXPA99011322A (es)
NO (2) NO995938L (es)
NZ (2) NZ523725A (es)
OA (1) OA11306A (es)
PE (1) PE78899A1 (es)
PL (1) PL337201A1 (es)
SK (1) SK164899A3 (es)
TR (2) TR200002790T2 (es)
TW (1) TW570797B (es)
UY (1) UY25032A1 (es)
WO (1) WO1998055122A1 (es)
ZA (2) ZA9811572B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20013800A3 (cs) * 1999-04-23 2002-04-17 Smithkline Beecham Plc Polymorf soli 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]-benzyl]thiazolidin-2,4-dionu s kyselinou maleinovou
DE60004658T2 (de) 1999-04-23 2004-06-24 Smithkline Beecham Plc, Brentford Thiazolidindionderivat und seine verwendung als antidiabetikum
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
DE06252444T8 (de) * 2006-05-09 2009-03-19 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
CN1083715C (zh) * 1994-02-10 2002-05-01 史密丝克莱恩比彻姆有限公司 胰岛素敏化物治疗肾病的应用
NZ313874A (en) * 1995-08-10 2000-09-29 Warner Lambert Co Compounds used as medicaments useful in eliminating the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
CN1230114A (zh) * 1996-07-12 1999-09-29 史密丝克莱恩比彻姆有限公司 Leptine抵抗的新疗法

Also Published As

Publication number Publication date
CA2292629C (en) 2004-01-06
PE78899A1 (es) 1999-10-22
AR015120A1 (es) 2001-04-18
ZA984826B (en) 1999-08-03
TR200002790T2 (tr) 2001-11-21
WO1998055122A1 (en) 1998-12-10
CN1259050A (zh) 2000-07-05
MXPA99011322A (es) 2004-12-02
GB9711683D0 (en) 1997-08-06
NZ513922A (en) 2001-09-28
NZ523725A (en) 2004-09-24
CA2292629A1 (en) 1998-12-10
EA199901116A1 (ru) 2000-06-26
TR199902963T2 (xx) 2000-02-21
CN1526391A (zh) 2004-09-08
IL133074A0 (en) 2001-03-19
ZA9811572B (en) 1999-07-22
NO995938L (no) 2000-02-02
SK164899A3 (en) 2000-11-07
CN1112926C (zh) 2003-07-02
JP2001521553A (ja) 2001-11-06
CA2333352A1 (en) 1998-12-10
HUP0004070A3 (en) 2002-03-28
NO995938D0 (no) 1999-12-03
AP9901696A0 (en) 1999-12-31
NO20040738L (no) 2000-02-02
BG104048A (bg) 2000-07-31
CN1430959A (zh) 2003-07-23
CO4940400A1 (es) 2000-07-24
EP0998284A1 (en) 2000-05-10
KR20010013410A (ko) 2001-02-26
AR008198A1 (es) 1999-12-29
DZ2510A1 (fr) 2003-01-25
UY25032A1 (es) 1998-11-26
BR9810405A (pt) 2000-08-29
HUP0004070A2 (hu) 2002-02-28
PL337201A1 (en) 2000-08-14
OA11306A (en) 2003-10-22
AP1214A (en) 2003-10-08
ID24264A (id) 2000-07-13
EA002384B1 (ru) 2002-04-25
AU8215098A (en) 1998-12-21

Similar Documents

Publication Publication Date Title
TW565449B (en) Pharmaceutical compositions for use in treating diabetes mellitus and conditions associated with diabetes mellitus
TWI331525B (en) Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
TW570797B (en) Pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus
JP2000507945A (ja) 痛みを処置する方法
TW200412934A (en) Pharmaceutical formulations of modafinil
NO168629B (no) Fremgangsmaate for fremstilling av oralt administrerbare, antidiabetisk virkende preparater
TW505516B (en) A pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus
JPH08504201A (ja) 抗うつ作用を有する医薬組成物としての２‐アミノ‐６‐ｎ‐プロピル‐アミノ‐４，５，６，７‐テトラヒドロベンゾチアゾールの使用
TW587937B (en) Pharmaceutical composition for treating diabetes mellitus and conditions associated with diabetes mellitus
JP3586471B2 (ja) トラセミド含有医薬組成物
EP1202737A2 (en) Antiviral therapy use of p-glycoprotein modulators
KR100366130B1 (ko) 항과혈당증작용을지닌약제
JPH0428245B2 (es)
TW542717B (en) Pharmaceutical compositions for use in treating diabetes mellitus and conditions associated with diabetes mellitus in a mammal
TW586926B (en) A pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal
JP3465247B2 (ja) 動脈硬化症の予防および治療剤
TW383222B (en) Pharmaceutical composition of bicycloheptane derivatives
JPH01193224A (ja) モクソニジンを含有する製薬学的組成物及びその製造法
JP2001502718A (ja) ラミブジンおよびジドブジンを含む医薬組成物
NZ514353A (en) Combination preparation for treating malaria
JP2020537689A (ja) Ａ−ノル−５αアンドロスタン化合物を含む白血球増多製剤およびその使用
JP2005532341A (ja) アバカビルとラミブジンを含有する医薬組成物
TW491702B (en) A novel antispasmodic and antiinflammatory composition and a process for the manufacture thereof
Specifications Standards
KR101262123B1 (ko) 지질 대사 이상의 예방 또는 치료용 의약 조성물

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees